Ferrum Lek, 100 mg 50 pcs.

Ferrum Lek is an anti-anemic drug.

Pharmacodynamics

The molecular weight of the complex is so large – about 50 kDa – that its diffusion through the gastrointestinal mucosa is 40 times slower than that of divalent iron. The complex is stable and does not release iron ions under physiological conditions. The iron in the multinuclear active zones of the complex is bound in a structure similar to that of the natural iron compound, ferritin. Because of this similarity, the iron of this complex is absorbed only by active absorption. The iron-binding proteins on the surface of the intestinal epithelium absorb iron (III) from the complex through competitive ligand exchange. Absorbed iron is mainly deposited in the liver, where it binds to ferritin. Later in the bone marrow it is incorporated into hemoglobin.

The iron (III) complex polymaltose hydroxide does not have the pro-oxidant properties of iron (II) salts.

Pharmacokinetics

Double isotope studies (⁵⁵Fe and ⁵⁹Fe) showed that iron absorption, as measured by hemoglobin levels in erythrocytes, is inversely proportional to the dose taken (the higher the dose, the lower the absorption). There is a statistically negative correlation between the degree of iron deficiency and the amount of iron absorbed (the higher the iron deficiency, the better the absorption). The greatest degree of iron absorption is in the duodenum and jejunum.

The remaining (unabsorbed) iron is excreted in the feces. Its excretion with the exfoliating cells of the gastrointestinal epithelium and skin, as well as with sweat, bile and urine is approximately 1 mg of iron per day. Women have additional iron loss during menstruation, which must be taken into account.

Indications

Composition

1 chewable tablet contains:

How to take, the dosage

Ingestion, during or immediately after a meal.

The chewable tablets of Ferrum Lek can be chewed or swallowed whole.

The daily dose can be divided into several doses or taken at one time.

The doses and duration of treatment depend on the degree of iron deficiency.

Interaction

Interaction with other drugs or food products has not been revealed.

Simultaneous use with parenteral iron preparations and other oral preparations of iron (III) hydroxide polymaltosate is not recommended due to marked inhibition of absorption of orally delivered iron.

Special Instructions

In children under 12 years of age, due to the need to prescribe low doses of the drug, it is preferable to prescribe Ferrum Lek in the form of syrup.

Neither chewable tablets nor Ferrum Lecne syrup cause staining of dental enamel.

In cases of anemia caused by infectious or malignant disease, iron accumulates in the reticulo-endothelial system, from which it is mobilized and utilized only after the underlying disease is cured.

When using the drug Ferrum Lec, the stools may become dark colored, which has no clinical relevance. Administration of iron preparations does not affect the results of the latent bleeding test (selective for hemoglobin).

Notice for diabetics: 1 chewable tablet or 1 ml of Ferrum Lek syrup contains 0.04 IU.

Notice for patients with phenylketonuria: Ferrum Lek contains aspartame (E951), which is a source of phenylalanine, in an amount equivalent to 1.5 mg per tablet.

The effect on the ability to drive a car or perform work requiring increased speed of physical and mental reactions.

The drug has no effect on the ability to concentrate.

Contraindications

Side effects

The reported adverse effects were mostly mild and transient.

According to the WHO, adverse reactions are classified according to their frequency of development as follows: very common (≥1/10), common (≥1/100,

Gastrointestinal disorders: very rare – abdominal pain, nausea, constipation, diarrhea, dyspepsia, vomiting, discoloration of feces (caused by excretion of not absorbed iron, not clinically relevant).

Skin and subcutaneous tissue disorders: very rare – urticaria, rash, itching of the skin.

Overdose

Symptoms: in case of overdose of Ferrum Lek syrup or chewable tablets no signs of intoxication or excess of iron in the body were observed, because iron from the active substance is not present in the gastrointestinal tract in free form and is not absorbed by passive diffusion.

Pregnancy use

In controlled studies in pregnant women (II, III trimesters of pregnancy) no adverse effects on the mother or fetus were observed.

No adverse effects on the fetus were found when taking the drug in the first trimester of pregnancy.

In controlled studies, when using the drug in the second and third trimesters of pregnancy, no adverse effects on the mother or fetus have been observed. No adverse effect on the fetus was found when using the drug in the I trimester of pregnancy.